Who is actually fighting to keep marijuana in Schedule I? According to the Justice Department, follow the money. In a new court filing defending rescheduling, DOJ argued that the groups trying to block the move have 'pocketbook interests' served by keeping all marijuana in Schedule I rather than any genuine public-health concern.
The opponents
The filing responds to a motion by two parties seeking to freeze rescheduling while their broader challenge plays out: NDASA, the National Drug and Alcohol Screening Association, and MMJ International Holdings, a cannabinoid-based biopharmaceutical company. DOJ laid out the financial interests it says are really at stake: drug screeners avoiding a loss of business, employers avoiding the cost of revising drug-testing protocols, and a pharmaceutical company preventing market competition.
DOJ's argument
The government did not just question the motives, it questioned the standing. For NDASA, DOJ said the group offered only 'generalized speculation' about industry impact without naming a single member with a concrete injury. For MMJ, DOJ argued the company cannot claim competitive harm because it does not yet have an authorized product on the market. And more broadly, DOJ said the alleged harms fall outside the purpose of the Controlled Substances Act, a law enacted to protect public health, not to guarantee revenue for drug screeners or protect future market opportunities for cannabinoid pharma.
The bigger picture
The argument lands as the DEA's rescheduling hearing, which opened June 29 with the government backing Schedule III, runs toward its July 15 deadline. The opposition has been loud and, as the selected participants showed, well-organized. DOJ's filing is a bet that when the motives are laid bare, the case against reform looks less like principle and more like protecting a business model. For adults 21 and over.